Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RPRX 
Royalty Pharma Plc (RPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RPRX (2-star) is a SELL. SELL since 1 days. Simulated Profits (7.56%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.86
1 Year Target Price $44.86
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.72% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.20B USD | Price to earnings Ratio 15.9 | 1Y Target Price 44.86 |
Price to earnings Ratio 15.9 | 1Y Target Price 44.86 | ||
Volume (30-day avg) 8 | Beta 0.57 | 52 Weeks Range 23.59 - 37.97 | Updated Date 09/16/2025 |
52 Weeks Range 23.59 - 37.97 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 2.37% | Basic EPS (TTM) 2.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 44.28% | Operating Margin (TTM) 38.85% |
Management Effectiveness
Return on Assets (TTM) 6.49% | Return on Equity (TTM) 17.29% |
Valuation
Trailing PE 15.9 | Forward PE 10.49 | Enterprise Value 22232628298 | Price to Sales(TTM) 9.2 |
Enterprise Value 22232628298 | Price to Sales(TTM) 9.2 | ||
Enterprise Value to Revenue 9.64 | Enterprise Value to EBITDA 11.51 | Shares Outstanding 432292992 | Shares Floating 379851580 |
Shares Outstanding 432292992 | Shares Floating 379851580 | ||
Percent Insiders 8.73 | Percent Institutions 82.45 |
Upturn AI SWOT
Royalty Pharma Plc
Company Overview
History and Background
Royalty Pharma was founded in 1996 and is the largest buyer of pharmaceutical royalties and related funding interests, helping innovators fund innovation. It acquires royalty streams from marketed and late-stage development-stage biopharmaceutical products.
Core Business Areas
- Acquisition of Royalties: Acquisition of royalty interests in marketed drugs and late-stage development products. This includes royalties on blockbuster drugs and promising new therapies.
- Funding of Clinical Trials: Providing funding to biotechnology and pharmaceutical companies to support clinical trials in exchange for royalties on future sales.
Leadership and Structure
The leadership team includes Pablo Legorreta (Founder & CEO), Terrance Cooke (EVP and CFO), and George Grose (EVP, General Counsel). The company operates under a board of directors with various committees.
Top Products and Market Share
Key Offerings
- Tysabri: Royalty interest in Tysabri (natalizumab), a treatment for multiple sclerosis. Competitors include Ocrevus, Gilenya, and Aubagio. Revenue and market share data are complex as Royalty Pharma only owns the royalty stream and not the drug itself. Competitors include Biogen and Novartis.
- Januvia/Janumet: Royalty interest in Januvia/Janumet (sitagliptin/sitagliptin/metformin), a treatment for type 2 diabetes. Competitors include other DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Royalty Pharma owns royalty interest on this medication. Competitors include Novo Nordisk and Eli Lilly.
- Tremfya: Royalty interest in Tremfya (guselkumab), a treatment for psoriasis and psoriatic arthritis. Competitors include Humira, Stelara, and Cosentyx. Royalty Pharma owns royalty interest on this medication. Competitors include Abbvie and Novartis.
Market Dynamics
Industry Overview
The royalty space within the pharmaceutical industry is growing. Innovator companies face increasing R&D costs and seek alternative funding options. Royalty Pharma provides non-dilutive capital.
Positioning
Royalty Pharma is a dominant player in the pharmaceutical royalty space, with a strong portfolio of royalty interests and a robust track record of successful acquisitions.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical royalties is estimated to be in the tens of billions of dollars annually, with the overall market driven by pharma R&D. Royalty Pharma is well-positioned to capitalize on this market.
Upturn SWOT Analysis
Strengths
- Diversified royalty portfolio
- Strong financial position
- Experienced management team
- Non-dilutive capital provider
Weaknesses
- Reliance on the success of underlying drugs
- Exposure to patent expirations
- Complex deal structures
- Dependence on the biopharmaceutical industry's success
Opportunities
- Increasing demand for non-dilutive financing
- Expansion into new therapeutic areas
- Partnerships with academic institutions
- Acquisition of additional royalty streams
Threats
- Drug price regulations
- Generic competition
- Clinical trial failures
- Changes in patent laws
Competitors and Market Share
Key Competitors
- DRIOW
- OMP
Competitive Landscape
Royalty Pharma is one of the largest in the pharmaceutical royalty space, benefiting from the size of their portfolio, but is still exposed to risks associated with patents expiring. They are well-positioned to capitalize on the growing demand for non-dilutive funding.
Major Acquisitions
Biohaven Pharmaceutical Holding Company Ltd.
- Year: 2022
- Acquisition Price (USD millions): 1300
- Strategic Rationale: Strategic rationale included gaining royalty rights to Nurtec ODT (rimegepant), a migraine treatment drug, which complemented Royalty Pharma's portfolio.
Growth Trajectory and Initiatives
Historical Growth: Growth trends can be analysed by reviewing the historical yearly revenue data.
Future Projections: Future projections are dependent on research on analyst ratings and estimates.
Recent Initiatives: Recent strategic initiatives need to be researched to give an appropriate answer.
Summary
Royalty Pharma is a strong player in the pharmaceutical royalty space due to its diversified portfolio and experienced management team. Its non-dilutive financing attracts growing demand. However, reliance on the success of underlying drugs and patent expirations pose key risks and they should monitor changes in drug price regulations to maintain its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Market research reports
- SEC filings
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. The market share information provided is an estimate and may vary. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Royalty Pharma Plc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1993-03-25 | Founder, Chairman of the Board & CEO Mr. Pablo Gerardo Legorreta | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.royaltypharma.com |
Full time employees - | Website https://www.royaltypharma.com | ||
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.